MegaMD메가엠디

MegaMD's trailing profits are thinner than in 2021, and the share price has fallen about 32% over the past year.

MegaMD is a Korean education company selling exam-preparation and professional certification courses, study guides and mock exams. For the twelve months to H1 2026 it reported revenue of about ₩34.7B, operating income of about ₩2.1B and net income of about ₩2.9B, with a cash balance of about ₩14.5B against borrowings of about ₩1.1B. The shares closed at ₩1,297 on 2026-10-23, with a market capitalisation of about ₩30.4B.

What stands out

• Revenue rose 10.2% in 2025 to about ₩34.6B, after a loss-making 2023 when operating income was about -₩2.8B.
• Operating margin was about 5.2% in 2025 and about 6% on a trailing basis, well below the 14.6% reached in 2021.
• Net income in 2024 and the trailing period was higher than operating income, so the bottom line relies on items other than core operations, which the data does not explain.
• The filings show a cash/stock dividend decision and an ex-dividend date in March 2026, and the data lists a dividend yield of about 4.6%.
• Foreign ownership rose from about 3.1% to 3.6% over 60 days, while foreign investors were net sellers over the last 20 days; no news headlines were available.

What to watch

• The full-year 2026 results and the next quarterly report, since the trailing figures only run to H1 2026.
• Whether operating margin recovers toward its 2021 level or stays near 5-6%.
• The company's value-up plan and any follow-up filings, as the data does not state its details.